Effectiveimmediately,CPT 31242 is no longer considered experimental, removing a key barrier for ENT physicians treating chronic rhinitis.
NeurentMedical, a leader in non-surgical treatments for chronic rhinitis, today announced thatUnitedHealthcare's Medicare Advantagepolicyhas removed CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list,effectiveimmediatelygiving over10 million patientsaccesstoNEUROMARK.
https://mma.prnewswire.com/media/2274744/Neurent_Medical_Logo.jpg
This policy update follows the recent Cigna coverage announcement (effective September 15) andrepresentsanotherimportant stepin improving patient access to innovative treatment options for chronic rhinitis and highlights growing payer recognition of the procedure's therapeutic value. While the update does notestablishclinical indications for coverage, iteliminatesa significant obstacle that previously limited physicians from offeringUnitedHealthcare's Medicare Advantagepatients posterior nasal nerve ablation.
“UnitedHealthcare's Medicare Advantage's policy change is another validation of the clinical need for modern, minimally invasive treatment options,” saidBrian Shields, CEO ofNeurentMedical. “We are committed to working with payers and providers to ensure that patients struggling with chronic rhinitis can access solutions that improve quality of life and reduce reliance on long-term medications.”
TheNEUROMARK System delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt parasympathetic nerve signals, addressing key symptoms of chronic rhinitis such as persistent nasal congestion and rhinorrhea (runny nose).
“This policy shift from UnitedHealthcare's Medicare Advantageis an important milestone for our specialty,” said Dr.Marc Dubin,MD,FACS.”By removing unnecessary administrative barriers, ENTs are better positioned to deliver evidence-based care that helps patients finally achieve relief from chronic rhinitis symptoms.”
Key Points for Providers:
— CPT 31242 is no longer classified as investigational byUnitedHealthcare's Medicare Advantage
— The policy supports more streamlined access to NEUROMARK for eligible patients
To viewUnitedHealthcare's Medicare Advantage's updated medical policy, visit:https://www.uhcprovider.com/content/dam/provider/docs/public/policies/medadv-mp/ear-nose-throat-procedures.pdf
For more information aboutNEUROMARK, visitwww.neuromark.comor contact your localNeurentMedical Sales Representative.
AboutNeurentMedical
Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK®technology, with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visitwww.neuromark.com.
PAM303October 2025
https://edge.prnewswire.com/c/img/favicon.png?sn=NE04417&sd=2025-10-22
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuromark-now-with-expanded-access-on-unitedhealthcares-medicare-advantage-policy-for-posterior-nasal-nerve-ablation-302591708.html
SOURCE Neurent Medical
https://rt.newswire.ca/rt.gif?NewsItemId=NE04417&Transmission_Id=202510221204PR_NEWS_USPR_____NE04417&DateId=20251022